Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer

Cancer

Volumn 115, Issue 22, 2009, Pages 5296-5308

  Du, Xianglin L ^a   Xia, Rui ^a   Liu, Chih Chin ^a   Cormier, Janice N ^b   Xing, Yan ^b   Hardy, Dale ^a   Chan, Wenyaw ^a   Burau, Keith ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Cardiotoxicity; Chemotherapy; Congestive heart failure; Medicare

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOXORUBICIN; FLUOROURACIL; TAXANE DERIVATIVE;

AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MASTECTOMY; MORBIDITY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; INCIDENCE; RISK;

EID: 70449372114     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24621     Document Type: Article

References (45)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.Lancet. 2005;365:1687-1717.
2. U.S. Food and Drug Administration. Managing the Risks From Medical Product Use. Pt III: How does FDA conduct postmarketing surveillance and risk assessment? Available at: http://www.fda.gov/oc/tfrm/Part3.html Accessed May 11, 2006.
3. Perry MC, Yarbro JW. Toxicity of chemotherapy. Orlando, Florida: Grune & Stratton;1984.
4. Baquiran DC. Lippincott's Cancer Chemotherapy Handbook. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
5. Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr. 1986;105-109.
6. Fisher B, Anderson S, DeCillis A, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol. 1999;17:3374-3388.
7. Shapiro CL, et al. Side Effects of Adjuvant Treatment of Breast Cancer. N Engl J Med. 2001;344:1997-2008. (Pubitemid 32568155)
8. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol. 2000;18:1412-1422.
9. Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr. 2001;135-142.
10. Goldberg RM, Sargent DJ, Morton RF, Mahoney MR, Krook JE, O'Connell MJ. Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program. J Clin Oncol. 2002;20:4591-4596.
11. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109:3122-3131.
12. Loerzel VW, Dow KH. Cardiac toxicity related to cancer treatment. Clin J Oncol Nurs. 2003;7:557-562.
13. Fumoleau P, Roché H, Kerbrat P, et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French adjuvant study group results. Ann Oncol. 2006;17:85-92. (Pubitemid 43033845)
14. Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25:3991-4008. (Pubitemid 47477279)
15. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol. 2007;50:1435-1441. (Pubitemid 47494586)
16. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21:1383-1389. (Pubitemid 46606420)
17. Ahmad SR. Adverse drug event monitoring at the Food and Drug Administration. J Gen Intern Med. 2003;18:57-60.
18. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285:437-443. (Pubitemid 32097262)
19. Kessler DA. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA. 1993;269:2765-2768. (Pubitemid 23154251)
20. Wu AW. Adverse drug events and near misses: who's counting? Am J Med. 2000;109:166-168.
21. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA. 1999;281:824-829. (Pubitemid 29113743)
22. Temple R. Meta-analysis and epidemiologic studies in drug development and postmarketing surveillance. JAMA. 1999;281:841-844. (Pubitemid 29113746)
23. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287:2215-2220.
24. Kaufman DW, Shapiro S. Epidemiological assessment of drug-induced disease. Lancet. 2000;356:1339-1343.
25. Agency for Healthcare Research and Quality. Research Activities. August 2004, No.288. Postmarketing drug surveillance could be improved. Available at: http://www.ahrq.gov/research/aug04/0804RA11.htm#head3 Accessed May 11,2006.
26. US Food and Drug Administration. Report to Congress: reports on postmarketing studies. Available at: http://www.fda.gov/cber/fdama/ pstmrktfdama130.htm Accessed May 11, 2006.
27. Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance - lack of vigilance, lack of trust. JAMA. 2004;292:2647-2650. (Pubitemid 39577521)
28. Griffin MR, Stein CM, Ray WA. Postmarketing surveillance for drug safety: surely we can do better. Clinical Pharmacology & Therapeutics. 2004;75:491-494. (Pubitemid 38746599)
29. Butler RN, Nyberg JP. Improving Drug Safety: The Importance of Postmarketing Drug Surveillance. Report Issue IB13-2004 of the International Longevity Center-USA. Available at: http://www.ilcusa.org/-lib/pdf/ postmarketing. pdf Accessed May 12, 2006.
30. US Food and Drug Administration. FDA acts to strengthen the safety program for marketed drugs [press release]. Available at: http://www.fda.gov/ bbs/topics/news/2004/ NEW01131.html Accessed May 12, 2006.
31. Doyle JJ, Neugut AI, Jacobson JS, et al. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005;23:8597-8605. (Pubitemid 46211501)
32. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25:3808-3815. (Pubitemid 47477254)
33. National Cancer Institute. Surveillance Epidemiology and End Results. Available at: http://seer.cancer.gov/index.html Accessed October 20, 2008.
34. U.S. Public Health Services. International Classification of Diseases, 9th Revision, Clinical Modification. 5th ed. Los Angeles, CA: Practice Management Information; 1996.
35. Du XL, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: Findings from Medicare claims data. J Clin Oncol. 2001;19:1455-1461.
36. Du XL, Freeman JL, Goodwin JS. Information on radiation treatment in patients with breast cancer: the advantages of the linked Medicare and SEER data. J Clin Epidemiol. 1999;52:463-470.
37. Du XL, Chan W, Giordano S, et al. Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicity. Cancer. 2005;104:913-924. (Pubitemid 41170217)
38. Penman AD, JohnsonWD. A SAS program for calculating cumulative incidence of events (with confidence limits) and number at risk at specified time intervals with partially censored data. Comput Methods Programs Biomed. 2008;89:50-55.
39. Bryant J, Picot J, Levitt G, Sullivan I, Baxter L, Clegg A. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Health Technol Assess. 2007;11:iii,ix-x,1-84.
40. Ganz PA, Hussey MA, Moinpour CM, et al. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol S8897. J Clin Oncol. 2008;26:1223-1230.
41. Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol.2008;26:1201-1203.
42. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26:1231-1238.
43. Steingart R. Mechanisms of late cardiovascular toxicity from cancer chemotherapy. J Clin Oncol. 2005;23:9051-9052. (Pubitemid 46260156)
44. Portera CC, Swain SM. The heart of the matter. J Clin Oncol. 2007;25:3794-3796.
45. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res. 2008;14:14-24.